Publication: Treatment of allergic rhinitis and urticaria: A review of the newest antihistamine drug bilastine
Issued Date
2016-04-13
Resource Type
ISSN
1178203X
11766336
11766336
Other identifier(s)
2-s2.0-84963800584
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Therapeutics and Clinical Risk Management. Vol.12, (2016), 585-597
Suggested Citation
Xue Yan Wang, Margaret Lim-Jurado, Narayanan Prepageran, Pongsakorn Tantilipikorn, De Yun Wang Treatment of allergic rhinitis and urticaria: A review of the newest antihistamine drug bilastine. Therapeutics and Clinical Risk Management. Vol.12, (2016), 585-597. doi:10.2147/TCRM.S105189 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/43356
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Treatment of allergic rhinitis and urticaria: A review of the newest antihistamine drug bilastine
Abstract
© 2016 Wang et al. Allergic rhinitis and urticaria are common allergic diseases that may have a major negative impact on patients’ quality of life. Bilastine, a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action. This agent does not interact with the cytochrome P450 system and does not undergo significant metabolism in humans, suggesting that it has very low potential for drug–drug interactions, and does not require dose adjustment in renal impairment. As bilastine is not metabolized and is excreted largely unchanged, hepatic impairment is not expected to increase systemic exposure above the drug’s safety margin. Bilastine has demonstrated similar efficacy to cetirizine and desloratadine in patients with seasonal allergic rhinitis and, in a Vienna Chamber study, a potentially longer duration of action than fexofenadine in patients with asymptomatic seasonal allergic rhinitis. It has also shown significant efficacy (similar to that of cetirizine) and safety in the long-term treatment of perennial allergic rhinitis. Bilastine showed similar efficacy to levocetirizine in patients with chronic spontaneous urticaria and can be safely used at doses of up to fourfold higher than standard dosage (80 mg once daily). The fourfold higher than standard dose is specified as an acceptable second-line treatment option for urticaria in international guidelines. Bilastine is generally well tolerated, both at standard and at supratherapeutic doses, appears to have less sedative potential than other second-generation antihistamines, and has no cardiotoxicity. Based on its pharmacokinetic properties, efficacy, and tolerability profile, bilastine will be valuable in the management of allergic rhinitis and urticaria.